Gaurav Shah is Chief Executive Officer and Director of Rocket Pharmaceuticals, Inc. (RCKT). The company reported total compensation of $3,510,241 for fiscal year 2025.
| Salary | $671,076 |
|---|---|
| Bonus | $0 |
| Stock awards | $806,751 |
| Option awards | $1,613,377 |
| Non-equity incentive plan | $403,048 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $15,988 |
| Total | $3,510,241 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Rocket Pharmaceuticals, Inc. filed April 6, 2026, accession 0001140361-26-013335.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer and Director | $671,076 | $0 | $806,751 | $1,613,377 | $403,048 | $0 | $15,988 | $3,510,241 |
| FY2024 | Chief Executive Officer | $635,880 | — | $1,997,976 | $4,001,997 | $190,764 | — | $14,790 | $6,841,407 |
Totals as disclosed in each year's own compensation disclosure for Rocket Pharmaceuticals, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Christopher Stevens | Chief Operating Officer | $3,555,467 |
| Gaurav Shah this page | Chief Executive Officer and Director | $3,510,241 |
| Martin Wilson | General Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial Officer | $3,397,880 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Rocket Pharmaceuticals, Inc. compensation brief.
Gaurav Shah's compensation sits inside Rocket Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.